NeurologyLive® Friday 5 — January 20, 2023

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 20, 2023.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: The Season of Giving, and Hope

In our NeurologyLive® print feature, the season of giving, gratitude, and, above all, hope is also the theme of our volume 5, 7th issue. Our featured articles look at chronic neurologic conditions and the pipeline of progress that can offer hope to millions of patients or reestablish evidence-based practice to put into practical clinical use.

The Season of Giving, and Hope

2: Peer Exchange: Factors Contributing to Clinical Trial Failures in Alzheimer’s Disease

In episode 8 of this Peer Exchange, the panel of experts in dementia discusses factors that may have contributed to the high failure rate of Alzheimer’s disease clinical trials thus far. The NeurologyLive® series panel features Marwan Sabbagh, MD; Alireza Atri, MD, PhD; Sharon Cohen, MD, FRCPC; and Eric McDade, DO.

Factors Contributing to Clinical Trial Failures in Alzheimer’s Disease

3: NeuroVoices: Rachel Alvarez on Cure CMD’s Goal to Bring Patients and Clinicians Together

In the latest edition of our in-depth Q&A series, the executive director of Cure CMD provided perspective on a new 10-month program that aims to align patient and clinician perspectives on certain rare neuromuscular disorders.

NeuroVoices: Rachel Alvarez on Cure CMD’s Goal to Bring Patients and Clinicians Together

4: Episode 80: Advancing Treatment for Rare Neuromuscular Disorders

In episode 80 of NeurologyLive®'s Mind Moments® podcast, brings you an exclusive interview with Sarah Boyce, president and CEO of Avidity Biosciences, who shared insight into the company's ongoing work with its antibody oligonucleotide conjugates (AOC) platform and the focus on myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD) treatments, as well as the challenges with developing successful RNA therapies, and more. [LISTEN TIME: 21 minutes]

Episode 80: Advancing Treatment for Rare Neuromuscular Disorders

5: Remote Monitoring Patients Through Smartphone Applications: Michelle Chen, PhD

The neuropsychologist at Rutgers University spoke on how remotely monitoring patients through a smartphone is a simple and effective application for data collection and also mentioned how assessing activities that patients do in their day-to-day life is able to reveal more about their brain functioning. [WATCH TIME: 3 minutes]

Remote Monitoring Patients Through Smartphone Applications: Michelle Chen, PhD

—————————————————

Nominations for Giants of Multiple Sclerosis® are open! This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in multiple sclerosis. Nominations close on January 31, 2023!

Nominate: neurologylive.com/Giants-of-MS

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.